Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: Jonathan Schonsheck who wrote (3712)	7/14/1998 12:33:00 PM
From: John H. Farro	Read Replies (1) \| Respond to of 4342

PRLN's contract with Scherer provides for its immediate survival and some good potential for future growth. Its agreement with the SRI plants the seeds for explosive growth in the future. I would expect it to take at least 3 - 5 years before PRLN will see any money for marketable cancer drugs. But I am glad they are finally able to do serious testing in humans with their drug candidates. This is something PRLN could not have done alone. BTW, did anyone notice the following: Southern Research also possesses a full-service HIV research and development capability and is developing novel new approaches in gene therapy. Is it possible that SRI may play a role in "The Son of Androvir"? Robin